New Haven Pharmaceuticals

New Haven Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary prescription drugs. The company's strategy involves utilizing well-established compounds, including those designated as Generally Recognized as Safe (GRAS), in combination with its proprietary controlled-release technologies to create new pharmaceutical products.

One of the company's notable achievements is the development and FDA approval of Durlaza, an extended-release aspirin capsule. This product is indicated for the secondary prevention of stroke and other acute cardiac events, targeting patients with cardiovascular disease. By creating a controlled-release formulation of a widely used and well-known drug like aspirin, New Haven Pharmaceuticals aims to offer improved therapeutic options for patients.

The company operates in the competitive pharmaceutical market, with a business model centered on the research, development, and commercialization of its proprietary drug formulations. As a privately held entity, its financial success is tied to the market adoption and sales of its products like Durlaza, which are prescribed by healthcare professionals and distributed through pharmacies.

Keywords: specialty pharmaceuticals, prescription drugs, controlled-release technology, Durlaza, extended-release aspirin, cardiovascular disease, stroke prevention, FDA approval, GRAS, drug development